Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Modern Management of DLBCL

New E-learning module by Ruth Pettengell now available. View the presentation and take the CME test.

Learning objectives

  • To provide an update on classification, molecular biology and outcomes of diffuse large B-cell lymphoma (DLBCL)
  • To provide an update on advances in first-line management of patients with DLBCL
  • To provide an update on management of patients with relapsed DLBCL

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Modern Management of DLBCL 54 min. 56 slides - -

Diffuse large B-cell lymphoma (DLBCL) is the most common form of B-cell lymphomas. The outcome of DLBCL has improved with the addition of rituximab (R) to CHOP chemotherapy regimen. Patients who fail R-CHOP have a dismal outcome. Selectivity of targeted agents underlines the importance of molecular subtyping at relapse. There is a plethora of new agents, but the studies generally include very few patients with DLBCL. This ESMO E-Learning module gives a short summary devoted to advances in the management of patients with DLBCL.

In terms of first-line treatment, the author emphasizes that we are getting closer to understanding the distinct biology of the different subtypes of lymphomas. R-CHOP remains the standard of care, but it is likely that in the future, in certain subgroups, R-CHOP will be combined with another therapy. The author underlines that it is unlikely to make progress with one-size-fits- all chemotherapy in patients with DLBCL.

Furthermore, the author states that there is the need to better understand prognostic markers in DLBCL, in order to better target therapies and design clinical trials.

In case of relapse, subtype and histology matter. Further factors to take into consideration are comorbidities, previous therapies, responses and duration of response, patient’s functional status, and patient’s preferences. In general, relapsed DLBCL has a poor prognosis. The author reviews the treatment possibilities in relapsed and refractory settings.

Overall, this module is an excellent opportunity to keep abreast with advances in the management of DLBCL. The author provides an overview of incidence, classification revision, prognosis and prognostic scores, treatment algorithms and updates on recent advances in first-line treatment and management of relapsed/refractory disease.

This E-Learning module was published in 2017 and expired in 2019.

Last update: 30 May 2017

The author has reported no conflicts of interest

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings